COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D PXPX FLVFLV PVP-IPI HC QHC Q BHBH CICI BLBL NZNZ COCO BUBU More..
Tweet (DB RCT)0.19[0.01-3.90]death0/1142/100RRCITreatmentControlCadegiani (DB RCT)0.08[0.04-0.17]viral+7/17134/66Tau​2 = 0.00; I​2 = 0.0%Early treatment0.08[0.04-0.18]7/28536/16692% improvementCadegiani (DB RCT)0.09[0.05-0.15]death12/294141/296RRCITreatmentControlTau​2 = 0.00; I​2 = 0.0%Late treatment0.09[0.05-0.15]12/294141/29691% improvementAll studies0.08[0.05-0.13]19/579177/46292% improvement3 proxalutamide COVID-19 4/16/21Tau​2 = 0.00; I​2 = 0.0%; Z = 10.74 (p < 0.0001)Lower RiskIncreased Risk
Late Cadegiani et al., Press Conference (Preprint) death, ↓91.4%, p<0.0001 The Proxa-Rescue AndroCoV Trial
RCT 590 hospitalized patients, 294 treated with proxalutamide showing significantly lower mortality and faster recovery.
Early Cadegiani et al., Cureus, doi:10.7759/cureus.13492 (Peer Reviewed) viral+, ↓92.1%, p<0.0001 Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial
RCT 234 mild-moderate COVID-19 patients with 171 treated with proxalutamide, showing significantly faster viral clearance and recovery.
Early Cadegiani et al., Research Square, doi:10.21203/ (Preprint) death, ↓81.1%, p=0.22 Proxalutamide (GT0918) Reduces the Rate of Hospitalization and Death in COVID-19 Male Patients: A Randomized Double-Blinded Placebo-Controlled Trial
RCT 214 male patients in Brazil, 114 treated with proxalutamide, showing significantly lower hospitalization and mechanical ventilation. NCT04446429.
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation.